Actively Recruiting
Open-label Study Evaluating Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy
Led by Kardigan, Inc. · Updated on 2026-11-04
332
Participants Needed
78
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating danicamtiv, an investigational medication, to understand its long-term safety and effectiveness in adults with symptomatic genetic or familial dilated cardiomyopathy DCM. This condition currently has no approved medicines specifically targeting its genetic or familial form. The study aims to explore how well danicamtiv works, its safety, and how well patients can tolerate it over extended use. Participants in this study will take danicamtiv twice daily for up to 5 years. The study involves a single group of participants all receiving the same investigational drug. Regular clinic visits, about 16 in total, will be scheduled for clinical evaluations and diagnostic tests to monitor treatment effects and safety throughout the study period. During the study, participants will undergo assessments including physical examinations, vital sign checks, electrocardiograms ECGs, and clinical laboratory tests. Researchers will also monitor changes in cardiac structure and function using transthoracic echocardiograms and evaluate quality of life through questionnaires such as the Kansas City Cardiomyopathy Questionnaire and EuroQol surveys. Safety will be closely tracked by recording adverse events and disease-related occurrences over the entire 61 months of follow-up.
CONDITIONS
Brief Title
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Research Team
K
Kardigan Clinical Trial Information Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here